Targeting CYP4F8: A Potential Approach To Cancer Therapies (G11283)

Target Name: CYP4F8

NCBI ID: G11283

CYP4F8

Targeting CYP4F8: A Potential Approach To Cancer Therapies

CYP4F8, also known as monooxygenase D2, is a gene that encodes for a protein known as CYP4F8. This protein is expressed in the liver and other tissues and is involved in the metabolism of various drugs, including many anti-cancer drugs.

One of the main functions of CYP4F8 is to metabolize the chemotherapy drug taxol, which is commonly used to treat breast cancer. Taxol is a taxane derivative that is inhibitor of tubulin inhibitors, which can cause cells to enter a state of mitosis that is more susceptible to chemotherapy drugs.

CYP4F8 is a critical enzyme in the metabolism of taxol, and studies have shown that individuals with genetic variations in the CYP4F8 gene are more likely to have reduced levels of taxol metabolites in their bodies. This suggests that individuals with these genetic variations may be more susceptible to the side effects of taxol.

In addition to its role in the metabolism of taxol, CYP4F8 is also involved in the metabolism of other drugs, including some statins, antidepressants, and beta blockers. This makes it an attractive drug target for researchers because these drugs can also cause side effects that are sensitive to genetic variations in the CYP4F8 gene.

One potential way to target CYP4F8 is through inhibition of the enzyme's activity. This can be done through a variety of methods, including inhibition of the enzyme's substrate, such as taxol, or through inhibition of the enzyme's activity by binding to its active site.

Another approach to targeting CYP4F8 is through manipulation of the gene's expression. This can be done through techniques such as RNA interference or CRISPR/Cas9 genome editing. By reducing the amount of CYP4F8 protein produced, researchers can reduce the impact of the enzyme on the body and potentially reduce the risk of side effects associated with its use.

In addition to its potential as a drug target, CYP4F8 is also a potential biomarker for monitoring the effectiveness of certain therapies. For example, if an individual is receiving chemotherapy treatment for breast cancer and has a genetic variation in the CYP4F8 gene, researchers can use CYP4F8 levels as a marker to track the effectiveness of the chemotherapy.

Overall, CYP4F8 is a gene that has significant implications for the development of drug targets and biomarkers. Its involvement in the metabolism of many drugs makes it an attractive target for researchers, while its role in the metabolism of taxol also makes it a potential target for the development of drugs that are more effective against cancer.

As research continues to advance, it is likely that the role of CYP4F8 in the metabolism of drugs will become increasingly important, and new therapies that target this gene will be developed. Researchers will continue to study the biology of CYP4F8 and its role in the metabolism of drugs, with the hope of using this knowledge to improve the health and well-being of people around the world.

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 8

Functions: A cytochrome P450 monooxygenase involved in the metabolism of endogenous polyunsaturated fatty acids (PUFAs) and their oxygenated derivatives (oxylipins). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes the hydroxylation of carbon hydrogen bonds, with preference for omega-1 and omega-2 positions (PubMed:10791960, PubMed:16112640, PubMed:15789615). Hydroxylates (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) predominantly at omega-2 position to form (18R)-hydroxyeicosatetraenoic acid (18R-HETE) (PubMed:10791960). Exhibits omega-1 hydroxylase activity toward prostaglandin (PG) H1, PGH2 and PGI2 (PubMed:10791960, PubMed:15789615). Catalyzes the epoxidation of double bonds of PUFAs, including docosahexaenoic and docosapentaenoic acids (PubMed:16112640). Shows little activity against PGD2, PGE1, PGE2, PGF2alpha, and leukotriene B4

The "CYP4F8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4F8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets